CAR-T疗法在前列腺癌中的治疗现状与应用前景  

Status and prospect of CAR-T cell therapy for prostate cancer

作　　者：黄家文 邹承宇 张亿达[1] Huang Jiawen;Zou Chengyu;Zhang Yida(Department of Urology,The First Affiliated Hospital of Nanchang University,Nanchang 330006,China;Nanchang University,Nanchang 330031,China)

机构地区：[1]南昌大学第一附属医院泌尿外科,南昌330006 [2]南昌大学,南昌330031

出　　处：《中华泌尿外科杂志》2022年第11期877-880,共4页Chinese Journal of Urology

基　　金：国家自然科学基金(82160474);江西省自然科学基金(20202BAB206018)。

摘　　要：目前,晚期前列腺癌的治疗已进入综合治疗的新时代,免疫检查点抑制剂在部分前列腺癌的治疗中表现出良好的疗效。细胞免疫疗法如嵌合抗原受体T细胞(CAR-T)疗法已在血液系统、消化系统恶性肿瘤中表现出优异效果,但其疗效在泌尿系统肿瘤中尚不明确。本文阐释CAR-T在前列腺癌中的治疗现状与应用前景,主要包括:嵌合抗原受体分子在前列腺癌中的靶标选择及困境、功能增强策略等,旨在为前列腺癌的细胞免疫治疗开拓新的视角和思路。At present,the treatment of advanced tumors has entered the immune era,and immune checkpoint inhibitors have shown good efficacy in prostate cancer.Cellular immunotherapy such as CAR-T therapy(chimeric antigen receptor T-cell immunotherapy)has shown excellent results in hematological and digestive system malignancies,but its efficacy in urinary system tumors is not yet clear.This review will explain the current status and application prospects of CAR-T in the treatment of prostate cancer,including target selection,predicament,and function enhancement strategies of CAR molecules in prostate cancer,aiming to open up new perspectives for cellular immunotherapy of prostate cancer and ideas.

关 键 词：前列腺肿瘤 癌 嵌合抗原受体-T细胞 免疫疗法 

分 类 号：R737.25[医药卫生—肿瘤]